Anneke C. Hesseling

15.3k total citations · 1 hit paper
275 papers, 8.4k citations indexed

About

Anneke C. Hesseling is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Anneke C. Hesseling has authored 275 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Infectious Diseases, 162 papers in Epidemiology and 66 papers in Surgery. Recurrent topics in Anneke C. Hesseling's work include Tuberculosis Research and Epidemiology (222 papers), Pneumocystis jirovecii pneumonia detection and treatment (87 papers) and Pneumonia and Respiratory Infections (69 papers). Anneke C. Hesseling is often cited by papers focused on Tuberculosis Research and Epidemiology (222 papers), Pneumocystis jirovecii pneumonia detection and treatment (87 papers) and Pneumonia and Respiratory Infections (69 papers). Anneke C. Hesseling collaborates with scholars based in South Africa, United States and United Kingdom. Anneke C. Hesseling's co-authors include H. Simon Schaaf, Ben J. Marais, Nulda Beyers, Robert P. Gie, Peter R. Donald, Donald A. Enarson, James A. Seddon, Anna M. Mandalakas, Anthony J. Garcia‐Prats and Gerhard Walzl and has published in prestigious journals such as The Lancet, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Anneke C. Hesseling

262 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era.

2004 607 citations Ben J. Marais, Robert P. Gie et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anneke C. Hesseling South Africa	50	7.0k	4.9k	3.4k	1.3k	569	275	8.4k
H. Simon Schaaf South Africa	57	9.5k 1.4×	6.7k 1.4×	5.2k 1.5×	976 0.8×	785 1.4×	324	11.6k
Timothy R. Sterling United States	51	9.1k 1.3×	6.6k 1.3×	3.5k 1.0×	612 0.5×	325 0.6×	244	11.6k
Graeme Meintjes South Africa	65	9.3k 1.3×	8.8k 1.8×	3.7k 1.1×	686 0.5×	282 0.5×	304	12.6k
Peter R. Donald South Africa	57	7.4k 1.1×	5.0k 1.0×	4.8k 1.4×	595 0.5×	490 0.9×	193	9.9k
Gary Maartens South Africa	62	10.4k 1.5×	6.5k 1.3×	3.2k 0.9×	587 0.5×	947 1.7×	376	14.0k
Hansjakob Furrer Switzerland	64	9.2k 1.3×	5.6k 1.1×	929 0.3×	529 0.4×	775 1.4×	276	14.3k
Marc Lipman United Kingdom	51	6.2k 0.9×	4.8k 1.0×	2.2k 0.6×	1.5k 1.2×	143 0.3×	292	9.2k
Gregory Hussey South Africa	43	4.5k 0.6×	3.5k 0.7×	1.2k 0.3×	2.4k 1.9×	414 0.7×	168	7.4k
Judith A. Aberg United States	51	5.9k 0.8×	3.0k 0.6×	982 0.3×	463 0.4×	326 0.6×	200	9.2k
Beate Kampmann United Kingdom	51	4.5k 0.6×	4.6k 0.9×	1.6k 0.5×	2.0k 1.6×	594 1.0×	280	9.6k

Countries citing papers authored by Anneke C. Hesseling

Since Specialization

Citations

This map shows the geographic impact of Anneke C. Hesseling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anneke C. Hesseling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anneke C. Hesseling more than expected).

Fields of papers citing papers by Anneke C. Hesseling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anneke C. Hesseling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anneke C. Hesseling. The network helps show where Anneke C. Hesseling may publish in the future.

Co-authorship network of co-authors of Anneke C. Hesseling

This figure shows the co-authorship network connecting the top 25 collaborators of Anneke C. Hesseling. A scholar is included among the top collaborators of Anneke C. Hesseling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anneke C. Hesseling. Anneke C. Hesseling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waalewijn, Hylke, Roeland E. Wasmann, Tim R. Cressey, et al.. (2025). Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas. The Lancet Child & Adolescent Health. 9(4). 274–282. 1 indexed citations

Wademan, Dillon T., Yael Hirsch‐Moverman, Lario Viljoen, et al.. (2025). Children and providers’ perspectives on once-weekly rifapentine and isoniazid TB preventive therapy. PubMed. 2(1). 13–18. 1 indexed citations

Hoddinott, Graeme, Heather R. Draper, Suzanne Staples, et al.. (2025). Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations. PubMed. 2(4). 208–216.

Seddon, James A., Neil Martinson, Lee Fairlie, et al.. (2025). Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment. PubMed. 2(3). 129–136. 1 indexed citations

Smith, Mariette, Regan Solomons, Ronald van Toorn, et al.. (2025). Incidence, Disease Spectrum, and Outcomes of Tuberculous Meningitis in South African Children: The Initial Impact of COVID-19. Tropical Medicine and Infectious Disease. 10(5). 127–127.

Hesseling, Anneke C., et al.. (2024). An item bank to measure health-related quality of life among young children (0-5-years-old) affected by respiratory illnesses – expert stakeholders and end-users from the Western Cape, South Africa. Health and Quality of Life Outcomes. 22(1). 95–95.

Wademan, Dillon T., Heather R. Draper, Megan Palmer, et al.. (2024). Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment. SHILAP Revista de lepidopterología. 1(2). 69–75. 3 indexed citations

Johnson, Linda, et al.. (2024). Health-related quality of life in children with presumptive TB. SHILAP Revista de lepidopterología. 1(11). 495–500.

Meehan, Sue‐Ann, et al.. (2023). TB programme stakeholder views on lessons from the COVID-19 response in South Africa. Public Health Action. 13(3). 97–103. 2 indexed citations

10.

Goussard, P., et al.. (2023). Phefumla Project: Identifying Challenges and Barriers in Outpatient Pulse Oximeter Implementation for Children in South Africa - Thematic Analysis of Healthcare Worker Interviews. A4632–A4632.

11.

Hesseling, Anneke C., H. Simon Schaaf, Megan Palmer, et al.. (2023). Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children. Journal of Antimicrobial Chemotherapy. 78(10). 2481–2488. 6 indexed citations

12.

Garcia‐Prats, Anthony J., H. Simon Schaaf, Maxwell Chirehwa, et al.. (2022). Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 66(6). e0226421–e0226421. 1 indexed citations

13.

Chabala, Chishala, Anna Turkova, Anneke C. Hesseling, et al.. (2021). Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations. Clinical Infectious Diseases. 74(10). 1767–1775. 17 indexed citations

14.

Garcia‐Prats, Anthony J., H. Simon Schaaf, Heather R. Draper, et al.. (2019). Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. PLoS Medicine. 16(4). e1002789–e1002789. 44 indexed citations

15.

Garcia‐Prats, Anthony J., Muhammad Osman, Heather R. Draper, et al.. (2019). Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. Antimicrobial Agents and Chemotherapy. 63(4). 19 indexed citations

16.

Garcia‐Prats, Anthony J., H. Simon Schaaf, Lubbe Wiesner, et al.. (2017). Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 62(2). 10 indexed citations

17.

Denti, Paolo, Anthony J. Garcia‐Prats, Heather R. Draper, et al.. (2017). Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 62(2). 38 indexed citations

18.

Harausz, Elizabeth, Anthony J. Garcia‐Prats, James A. Seddon, et al.. (2017). New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. American Journal of Respiratory and Critical Care Medicine. 195(10). 1300–1310. 54 indexed citations

19.

Mandalakas, Anna M., H. Lester Kirchner, Gerhard Walzl, et al.. (2015). Optimizing the Detection of Recent Tuberculosis Infection in Children in a High Tuberculosis–HIV Burden Setting. American Journal of Respiratory and Critical Care Medicine. 191(7). 820–830. 35 indexed citations

20.

Hesseling, Anneke C., Leigh F. Johnson, Heather B. Jaspan, et al.. (2009). Disseminated Bacille Calmette-Guerin Disease in HIV-Infected South African infants/Infection Disseminee Par le Bacille De Calmette-Guerin Chez Les Nourrissons Infectes Par le VIH d'Afrique Du Sud/Infeccion Diseminada Por El Bacilo De Calmette-Guerin En Lactantes Infectados Por El VIH En Sudafrica. Bulletin of the World Health Organization. 87(7). 505. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact